קובאלטרי iu 500
bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii
קוג'נייט fs 250 iu
bayer israel ltd - antihemophilic factor (recombinant) sucrose 250 iu/vial - powder for solution for injection - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.
רקומבינאט iu 250
teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
רקומבינאט iu 1000
teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
רקומבינאט iu 500
teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
אדוייט iu 250
takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 250 iu/vial - coagulation factor viii
אוקטאפלקס iu 500
dover medical & scientific equipment ltd, israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein; protein c; protein s antigen - אבקה וממס להכנת תמיסה לאינפוזיה - coagulation factor ix (human- rfixfc) 25 iu/ml; coagulation factor ii (human) 14 - 38 iu/ml; coagulation factor vii (human) 9 - 24 iu/ml; coagulation factor x (human) 18 - 30 iu/ml; protein 13 - 41 mg/ml; protein c 13 - 31 iu/ml; protein s antigen 12 - 32 iu/ml - coagulation factor ix, ii, vii and x in combination
אלוקטט 1000
sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 1000 iu - coagulation factor vii
אלוקטט 1500
sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 1500 iu - coagulation factor viii
אלוקטט 2000
sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 2000 iu - coagulation factor viii